@Article{ecn.2007.0098,
AUTHOR = {Cristina Tena-Tomás, Maria Lucia Pedroso, Iara J. de Messias-Reason, Peter G. Kremsner, Jürgen F. J. Kun},
TITLE = {Polymorphisms in the IFNAR1 gene in patients with chronic hepatitis C: outcome of combined IFN-a therapy},
JOURNAL = {European Cytokine Network},
VOLUME = {18},
YEAR = {2007},
NUMBER = {3},
PAGES = {19--24},
URL = {http://www.techscience.com/ECN/v18n3/65976},
ISSN = {1952-4005},
ABSTRACT = {Aims. Interferon-a (IFN-α) alone or in combination with ribavirin has been used for the last decade
in the treatment of chronic hepatitis C, although the achievement of a sustained virological response (SVR) has
not been very satisfactory. The treatment outcome depends on viral genotypes and host genetic polymorphisms
in genes involved in the IFN-α signaling cascade. In this paper, we investigated the distribution of two variants of
the IFNAR1 gene, G17470C and L168V, in two patient groups having received IFN-α alone or in combination with
ribavirin. Methods. The analysis was performed using DNA sequencing of the relevant gene fragments. Results and
conclusions. This study suggests that when combination therapy with high dose IFN-α and ribavirin is
administered, HCV genotypes and age rather than the IFNAR1 polymorphisms are the predictors of a sustained
response.},
DOI = {10.1684/ecn.2007.0098}
}